We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ALGN:NASDAQAlign Technology, Inc. Analysis

Data as of 2026-03-14 - not real-time

$164.23

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Align Technology delivered a strong fourth‑quarter beat, with revenue up 5.3% YoY and adjusted EPS rising 34.8% to $3.29, prompting analysts to lift their forecasts and maintain a consensus "Buy" rating. The company’s gross margin of 69.8% and operating margin of 22.4% underscore the high‑margin nature of its clear‑aligner and iTero scanner businesses, while cash on hand exceeds $1 billion and free cash flow remains robust at $483 million. However, the current price of $164.23 sits well above the DCF‑derived fair value of $128.70, implying a ~22% downside, and the trailing PE of 29x exceeds the industry average of 26x, signaling an overvalued valuation.
Technical indicators show the stock trading near its 20‑day SMA of $181.6 but below the 50‑day SMA of $175.0, with a bearish MACD histogram and an RSI of 36, suggesting short‑term oversold conditions but lingering bearish momentum. The beta of ~1.2 and 30‑day volatility of ~52% point to heightened price swings, while increasing volume and a bullish trend direction indicate continued market interest. Given the strong fundamentals but elevated valuation and risk profile, the outlook balances growth potential against price pressure.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Recent earnings beat but price above fair value
  • Bearish MACD and RSI near oversold levels
  • Support around $162.33 and rising volume

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Revenue growth and expanding margins
  • Forward PE of 13.4 indicating earnings upside
  • Analyst consensus upgrade and positive earnings outlook

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Sustainable competitive moat in clear aligners and digital imaging
  • Regulatory and reimbursement environment stability
  • Valuation premium relative to peers

Key Metrics & Analysis

Financial Health

Revenue Growth5.30%
Profit Margin10.17%
P/E Ratio29.1
ROE10.39%
ROA6.94%
Debt/Equity2.83
P/B Ratio2.9
Op. Cash Flow$593.2M
Free Cash Flow$483.7M
Industry P/E26.2

Technical Analysis

TrendBullish
RSI36.7
Support$162.33
Resistance$192.69
MA 20$181.61
MA 50$175.04
MA 200$159.95
MACDBearish
VolumeIncreasing
Fear & Greed Index72.88

Valuation

Fair Value$128.70
Target Price$201.57
Upside/Downside22.74%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta1.23
Volatility51.96%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.